We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesAgentix Corp

Agentix Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0337 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
30000
Market Cap
0.80M

Momentum Score

…

Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company has licensing agreement with National Health Research Institute and Research Triangle Institute. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.03
Low
0.04
High
52 Week Price Range
0.01
Low
0.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Agentix Corp (AGTX.US) is a microcap issuer quoted on the OTC Pink market for which public filings and a clear business description are limited or unavailable. Because its core activities and financials are not well documented, long-term growth drivers are not publicly disclosed, though investors may be attracted by potential upside typical of low-liquidity microcap stocks if corporate disclosures or operational execution materially improve.
Material risks include sparse public disclosure and limited audited financial reporting, low market liquidity, potential for significant dilution, and elevated execution and regulatory uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.03
Dividend Yield
-
Revenue TTM
-0.00M
Revenue Per Share
-
Gross Profit TTM
-0.08M
Debt / Equity
-0.10
ROE
-
Net Debt
0.35M
ROCE
12.38%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-08-31 2023-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-08-31 2023-03-31
Income before tax -0.49M -0.57M -0.59M -1.37M -1.37M
Net income -0.49M -0.57M -0.59M -1.37M -1.37M
Selling general administrative 0.32M 0.33M 0.57M 0.66M 0.66M
Gross profit - - 0.00M 0.00M 0.00M
Ebit - -1.04M - -1.37M -1.37M
Ebitda -0.45M -0.51M - -1.37M -1.37M
Depreciation and amortization - 0.51M - - 0.02M
Operating income -0.45M -0.51M -0.74M -1.37M -1.37M
Other operating expenses 0.45M 0.51M - 1.37M 1.37M
Interest expense 0.08M 0.04M 0.02M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.00M 0.00M 0.00M - 0.00M
Net interest income -0.08M -0.04M -0.02M -0.00M -0.00M
Income tax expense - - - 0.00M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 0.45M 0.51M 0.74M 1.37M 1.37M
Cost of revenue - - 0.00M 0.00M 0.00M
Total other income expense net -0.04M -0.05M 0.18M -0.00M -0.00M
Net income from continuing ops -0.49M -0.57M -0.59M -1.37M -1.37M
Net income applicable to common shares - - - -1.37M -1.37M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-08-31 2023-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-08-31 2023-03-31
Total assets 0.00M 0.10M 0.11M 0.26M 0.26M
Other current assets - 0.10M - 0.25M 0.25M
Total liab 3.60M 3.20M 2.67M 2.51M 2.51M
Total stockholder equity -3.60M -3.10M -2.56M -2.25M -2.25M
Other current liab 2.16M 1.62M - 1.45M -1.00M
Common stock 0.04M 0.04M - 0.04M 0.04M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.04M
Retained earnings -7.01M -6.52M -5.95M -5.37M -5.37M
Cash 0.00M 0.00M 0.01M 0.01M 0.01M
Total current liabilities 3.60M 3.20M 2.67M 2.51M 2.51M
Current deferred revenue - - - -1.44M -1.44M
Net debt 0.35M 0.24M 0.14M 0.04M 0.04M
Short term debt 0.35M 0.24M - 0.05M 0.05M
Short long term debt 0.35M 0.24M 0.14M 0.05M 0.05M
Short long term debt total 0.35M 0.24M - 0.05M 0.05M
Other stockholder equity 3.34M 3.29M - 3.08M 3.08M
Total current assets 0.00M 0.10M 0.11M 0.26M 0.26M
Net tangible assets - - - -2.25M -2.25M
Accounts payable 1.09M 1.34M 2.50M 2.45M 2.45M
Accumulated other comprehensive income 0.03M 0.09M - 0.00M 0.00M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-08-31 2023-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-08-31 2023-03-31
Investments - 0.00M 0.00M 0.00M 0.00M
Change to liabilities - - - 1.37M 1.37M
Net borrowings 0.11M 0.10M - - -
Total cash from financing activities 0.11M 0.10M 0.09M 0.10M 0.10M
Change to operating activities - - - -0.22M -0.22M
Net income -0.49M -0.57M -0.59M -1.37M -1.37M
Change in cash -0.00M -0.00M -0.01M 0.01M 0.01M
Begin period cash flow 0.00M 0.01M 0.01M 0.00M 0.00M
End period cash flow 0.00M 0.00M 0.01M 0.01M 0.01M
Total cash from operating activities -0.11M -0.13M -0.11M -0.09M -0.09M
Issuance of capital stock - - 0.00M 0.05M 0.05M
Depreciation - - - 0.02M 0.02M
Other cashflows from financing activities 0.11M - - 0.05M 0.05M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.40M 0.44M 0.18M 1.15M 1.15M
Other non cash items -0.02M - 0.29M 0.12M 0.12M
Free cash flow -0.11M -0.13M -0.11M -0.09M -0.09M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AGTX
Agentix Corp		 -
-%		 0.03 - - 2147.54 3587.45 2261.30 -1.39
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Agentix Corp

Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company has licensing agreement with National Health Research Institute and Research Triangle Institute. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.

32932 Pacific Coast Highway, Dana Point, CA, United States, 92629

321 299 2014

https://www.agentixcorp.com

Name Title Year Born
Mr. Rudy A. Mazzocchi B.Sc. Pres, CEO, Chairman, Principal Accounting Officer 1959
Mr. Salman Hoda Sr. VP Portfolio & Bus. Devel., Sec., Treasurer and Director 1981
Martin Schroeder Chief Scientific Officer & Member of Scientific Advisory Board NA
Mr. David Fiene Controller NA
Mr. Riazul Huda CEO, CFO & Director 1969
Mr. Martin Schroeder Chief Scientific Officer & Member of Scientific Advisory Board 1953
Mr. David Fiene Financial Controller NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PARA
USD 0.10
+38.58%
LUNR
USD 13.91
+14.20%
MBGL
USD 22.63
+13.60%
FRMI
USD 2.04
+12.71%
FIGR
USD 26.97
+11.49%
CDNL
USD 6.09
-59.37%
ADIG
USD 11.79
-39.79%
CTVA
USD 9.21
-24.11%
BZ
USD 12.99
-22.28%
ENVX
USD 1.98
-21.70%

Equity Sectors*

  • Basic Materials

    -1.40%

  • Communication Services

    -0.45%

  • Consumer Cyclical

    -0.55%

  • Consumer Defensive

    -0.01%

  • Energy

    -0.01%

  • Financial Services

    -0.40%

  • Financials

    -0.15%

  • Healthcare

    -1.15%

  • Industrials

    -0.46%

  • Real Estate

    -0.29%

  • Technology

    -1.22%

  • Utilities

    -0.10%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…